Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedFeb 15, 2026
DataAggregated Company Financials
Companies62
- 7D5.6%
- 3M-14.4%
- 1Y105.5%
- YTD4.7%
In the last week, the Biotech industry is up 5.6%, with Shanghai Bao Pharmaceuticals leading the way, up 50%. This takes the industry's 12 month performance to a gain of 105%. Looking forward, earnings are forecast to grow by 36% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 15 Feb 2026 | HK$997.5b | HK$71.0b | -HK$14,335,023,709.20 | 37x | -69.6x | 14.1x |
| Tue, 13 Jan 2026 | HK$1.0t | HK$70.3b | -HK$13,886,172,976.06 | 40.3x | -74.7x | 14.8x |
| Thu, 11 Dec 2025 | HK$963.7b | HK$69.3b | -HK$12,935,008,073.69 | 40.5x | -74.5x | 13.9x |
| Sat, 08 Nov 2025 | HK$972.8b | HK$68.7b | -HK$12,801,431,008.37 | 36.9x | -76x | 14.2x |
| Mon, 06 Oct 2025 | HK$1.1t | HK$68.4b | -HK$12,902,028,234.88 | 58.4x | -88.5x | 16.7x |
| Wed, 03 Sep 2025 | HK$1.1t | HK$68.0b | -HK$13,668,013,620.42 | 46.5x | -81x | 16.3x |
| Fri, 01 Aug 2025 | HK$972.1b | HK$63.6b | -HK$12,480,790,149.34 | 42.5x | -77.9x | 15.3x |
| Sun, 29 Jun 2025 | HK$723.0b | HK$63.7b | -HK$11,738,000,029.52 | 30.4x | -61.6x | 11.4x |
| Tue, 27 May 2025 | HK$598.2b | HK$62.1b | -HK$11,738,301,850.31 | 31.1x | -51x | 9.6x |
| Thu, 24 Apr 2025 | HK$569.3b | HK$60.3b | -HK$12,141,257,693.36 | 30.7x | -46.9x | 9.4x |
| Sat, 22 Mar 2025 | HK$464.4b | HK$52.9b | -HK$16,899,036,991.92 | 22.3x | -27.5x | 8.8x |
| Mon, 17 Feb 2025 | HK$383.0b | HK$52.2b | -HK$17,364,199,594.37 | 14.2x | -22.1x | 7.3x |
| Wed, 15 Jan 2025 | HK$353.1b | HK$51.7b | -HK$16,886,791,563.70 | 12.2x | -20.9x | 6.8x |
| Fri, 13 Dec 2024 | HK$405.5b | HK$52.1b | -HK$17,317,776,756.08 | 11.3x | -23.4x | 7.8x |
| Sun, 10 Nov 2024 | HK$403.2b | HK$52.5b | -HK$17,637,137,036.48 | 11.6x | -22.9x | 7.7x |
| Tue, 08 Oct 2024 | HK$445.4b | HK$52.9b | -HK$18,143,085,062.73 | 13.1x | -24.5x | 8.4x |
| Thu, 05 Sep 2024 | HK$338.8b | HK$52.5b | -HK$19,512,112,816.92 | 11.2x | -17.4x | 6.5x |
| Sat, 03 Aug 2024 | HK$321.6b | HK$50.0b | -HK$19,621,133,103.77 | 11.6x | -16.4x | 6.4x |
| Mon, 01 Jul 2024 | HK$327.6b | HK$49.6b | -HK$19,441,769,600.62 | 12.1x | -16.9x | 6.6x |
| Wed, 29 May 2024 | HK$338.7b | HK$49.8b | -HK$19,505,887,561.30 | 11.3x | -17.4x | 6.8x |
| Fri, 26 Apr 2024 | HK$346.9b | HK$49.5b | -HK$19,469,847,113.03 | 11.8x | -17.8x | 7x |
| Sun, 24 Mar 2024 | HK$345.6b | HK$49.7b | -HK$19,699,938,439.12 | 14.1x | -17.5x | 7x |
| Tue, 20 Feb 2024 | HK$329.9b | HK$46.8b | -HK$20,168,860,809.96 | 16.4x | -16.4x | 7.1x |
| Thu, 18 Jan 2024 | HK$354.3b | HK$46.8b | -HK$20,184,432,385.00 | 17x | -17.6x | 7.6x |
| Sat, 16 Dec 2023 | HK$406.3b | HK$47.2b | -HK$20,376,104,618.00 | 17.9x | -19.9x | 8.6x |
| Mon, 13 Nov 2023 | HK$417.3b | HK$45.2b | -HK$18,924,858,618.00 | 13.5x | -22.1x | 9.2x |
| Wed, 11 Oct 2023 | HK$380.4b | HK$44.9b | -HK$19,115,913,057.00 | 13.3x | -19.9x | 8.5x |
| Fri, 08 Sep 2023 | HK$400.2b | HK$44.9b | -HK$18,889,389,617.00 | 15.3x | -21.2x | 8.9x |
| Sun, 06 Aug 2023 | HK$398.2b | HK$35.6b | -HK$23,393,254,800.00 | 22.3x | -17x | 11.2x |
| Tue, 04 Jul 2023 | HK$392.4b | HK$35.3b | -HK$23,202,884,962.00 | 25.7x | -16.9x | 11.1x |
| Thu, 01 Jun 2023 | HK$412.8b | HK$35.9b | -HK$23,645,687,154.00 | 26.8x | -17.5x | 11.5x |
| Sat, 29 Apr 2023 | HK$445.1b | HK$36.9b | -HK$23,365,935,236.00 | 17.8x | -19.1x | 12.1x |
| Mon, 27 Mar 2023 | HK$430.5b | HK$35.1b | -HK$35,058,747,287.00 | 22.5x | -12.3x | 12.3x |
| Wed, 22 Feb 2023 | HK$417.7b | HK$34.5b | -HK$34,860,112,837.00 | 33.1x | -12x | 12.1x |
Price to Earnings Ratio
-12x
Current Industry PE
- Investors are optimistic on the Hong Kong Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 10.0x is lower than the industry's current PS ratio of 14.1x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 27% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 0.51% | |
| Healthcare | 3.53% | |
| Biotech | 5.62% | |
| Biotech | 5.62% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2659 Shanghai Bao Pharmaceuticals | HK$166.50 | 50.0% +HK$18.1b | n/a | PS1027.9x | |
| 1801 Innovent Biologics | HK$88.60 | 11.4% +HK$15.8b | 136.3% | PE120x | |
| 9926 Akeso | HK$105.30 | 4.4% +HK$4.1b | 74.9% | PS34.1x | |
| 2696 Shanghai Henlius Biotech | HK$70.35 | 10.3% +HK$3.6b | 234.2% | PE41x | |
| 2315 Biocytogen Pharmaceuticals (Beijing) | HK$53.50 | 12.2% +HK$2.6b | 555.6% | PE159.8x |